Drug Profile
Research programme: infectious diseases vaccines - Crucell/Pepscan Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Crucell; Pepscan Therapeutics
- Class Peptides; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Infections in Netherlands (Parenteral)
- 10 Mar 2011 Early research in Infections in Netherlands (Parenteral)
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson